Literature DB >> 6115248

Defective immune-adherence (C3b) receptor on erythrocytes from patients with systemic lupus erythematosus.

Y Miyakawa, A Yamada, K Kosaka, F Tsuda, E Kosugi, M Mayumi.   

Abstract

Erythrocytes from 56 patients with systemic lupus erythematosus (SLE) were tested for the immune-adherence (C3b) receptor reactivity for incubation with aggregated human gamma-globulin (AHG) in the presence of complement. The reactivity of the C3b receptors was expressed as the highest two-fold dilution of AHG that induced haemagglutination. Erythrocytes from 37 (66%) of the SLE patients failed to show any detectable reactivity with AHG, whereas the erythrocytes of only 1 of 51 normal controls matched for age and sex were found to be unreactive. The defect of the C3b receptor reactivity was persistent and could not be restored even after SLE patients had gone into remission with steroid therapy. Moreover, the defect was found frequently in the relatives of patients without detectable immune-adherence reactivity. Owing to its high prevalence and persistence in SLE, the defective erythrocyte C3b receptor may be a useful marker for identifying SLE patients and those predisposed to the disease.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6115248     DOI: 10.1016/s0140-6736(81)90882-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  60 in total

1.  In vivo binding of circulating immune complexes by C3b receptors (CR1) of transfused erythrocytes.

Authors:  Y Inada; M Kamiyama; T Kanemitsu; H Ikegami; K Watanabe; W S Clark; Y Asai
Journal:  Ann Rheum Dis       Date:  1989-04       Impact factor: 19.103

2.  Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment.

Authors:  R P Taylor; W M Sutherland; C J Reist; D J Webb; E L Wright; R H Labuguen
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

3.  Opsonized streptococcal cell walls cross-link human leukocytes and erythrocytes by complement receptors.

Authors:  K B Pryzwansky; J D Lambris; E K MacRae; J H Schwab
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

4.  Polymorphism of human erythrocyte C3b/C4b receptor.

Authors:  T R Dykman; J L Cole; K Iida; J P Atkinson
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

5.  Autoantibody to the C3b/C4b receptor and absence of this receptor from erythrocytes of a patient with systemic lupus erythematosus.

Authors:  J G Wilson; R M Jack; W W Wong; P H Schur; D T Fearon
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

6.  Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.

Authors:  Kazi Abdus Salam; Richard Y Wang; Teresa Grandinetti; Valeria De Giorgi; Harvey J Alter; Robert D Allison
Journal:  Hepatology       Date:  2018-11-01       Impact factor: 17.425

7.  Erythrocyte complement receptor type 1 in non-SLE rheumatic diseases.

Authors:  J H Yen; H W Liu; S F Lin; T P Chen
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

8.  Normal C3b receptor (CR1) genomic polymorphism in patients with insulin-dependent diabetes mellitus (IDDM): is the low erythrocyte CR1 expression an acquired phenomenon?

Authors:  P E Ruuska; I Ikäheimo; S Silvennoinen-Kassinen; M L Käär; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

9.  Defective erythrocyte C3b receptor function associated with low serum complement (C3, C4) concentrations in insulin-dependent diabetes mellitus.

Authors:  P Ruuska; J Ilonen; A Mustonen; A Tiilikainen
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

10.  Evidence for intrinsic cellular defects of 'complement' receptor-mediated phagocytosis in patients with systemic lupus erythematosus (SLE).

Authors:  N P Hurst; G Nuki; T Wallington
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.